Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central nervous program, conolidine modulates alternate molecular targets. A Science Developments study observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://zacka540ldn0.wikiusnews.com/user